Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on Synthomer

(Sharecast News) - Analysts at Berenberg lowered their target price on chemicals company Synthomer from 375.0p to 340.0p on Wednesday after the group's interim earnings "delivered both grounds for hope and reasons for caution". Berenberg stated on the one hand, the two units with the most scope for improvement - adhesives and nitrile - drove year-on-year increases in the underlying earnings of their parent segments.

"Due to a combination of restocking, self-help measures in adhesive solutions and improving volumes in nitrile latex supported results, volumes at the group level rose by circa 10% year-on-year, comfortably ahead of peers such as BASF," said Berenberg, which added that spreads in nitrile latex also appeared to have expanded during Q2.

On the other hand, the German bank, which has a 'buy' rating on the stock, noted that construction demand was subdued, leverage high at roughly £560.0m and said that generating positive free cash flow after a £31.0m negative result in H124 may prove difficult on a full-year basis.

However, Berenberg believes the nitrile recovery should shield the stock from macro headwinds in H224, and noted that few peers were as exposed as Synthomer to eventual macro recovery.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Smith & Nephew appoints Ajay Dhankhar as chief corporate development & strategy officer
(Sharecast News) - Medical technology company Smith & Nephew said on Monday that it has appointed Ajay Dhankhar as chief corporate development & strategy officer with immediate effect.
Oxford Biomedica acquires last 10pc stake in US subsidiary
(Sharecast News) - Oxford Biomedica said on Monday it has acquired the remaining 10% stake in its US subsidiary, OXB US, from Q32 Bio, bringing its ownership of the business to 100% as previously planned.
PPHE acquiring prime London site for hotel development
(Sharecast News) - PPHE Hotel Group has announced the acquisition of a prime development site near the City of London, where it plans to build its first Radisson RED select service hotel in the capital.
Norcros to end tile production in South Africa
(Sharecast News) - Norcros announced on Monday that it will shut down manufacturing at Johnson Tiles South Africa at the end of June, following the conclusion of a strategic review.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.